Výsledky vyhledávání - "Fatima Fuerte"

Supplementary Figure 1 from Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Supplementary Figure 1. (A) PFS in the cfDNA mut+ subgroup (B) OS in the cfDNA mut+ subgroup (C) PFS in the cfDNA mut+ subgroup (patients with no tissue result) (D) OS in the cfDNA mut+ subgroup (patients with no tissue result) (E) PFS in the cfDNA m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99267496a9f0d581dbea95dfc1b10c8e
https://doi.org/10.1158/1078-0432.22459443.v1

Zobrazit plný text záznamu

Supplementary Tables 1-4 from Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Supplementary Tables 1-4. Supplementary Table 1. Concordance, sensitivity, specificity, positive and negative predictive values of tissue and cfDNA tests (n=238) by EGFR mutation type Supplementary Table 2: EGFR mutation type Supplementary Table 3: E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4987cacd97c4d34db3f643a69c08b68
https://doi.org/10.1158/1078-0432.22459440

Zobrazit plný text záznamu

Data from Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study.Experimental Design: Patients were

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd7c00c885259dc1fc67b73bb4dbefa
https://doi.org/10.1158/1078-0432.c.6524220

Zobrazit plný text záznamu

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial

Publikováno v: The Lancet Oncology. 14:777-786

Summary Background The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60dab8836abdad4cf53d126062652ba7
https://doi.org/10.1016/s1470-2045(13)70254-7

Zobrazit plný text záznamu

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

Autor: Sumitra Thongprasert, Jin Soo Lee, Guia Ladrera, Pablo Perez-Moreno, Chong-Jen Yu, David S. Shames, Fatima Fuerte, Virote Sriuranpong, Yi-Long Wu, Matt Truman, Vichien Srimuninnimit, Jennifer Sandoval-Tan, Barbara Klughammer, Tony Mok

Publikováno v: Lung cancer (Amsterdam, Netherlands). 98

ObjectivesThe FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further explora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4147545459d1a3ee73495b2fe0978a7
https://pubmed.ncbi.nlm.nih.gov/27393499

Zobrazit plný text záznamu

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 21(14)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac72e4a1291e13ead4de16ea7bc1d0b6
https://pubmed.ncbi.nlm.nih.gov/25829397

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání